---
title: "Eton Pharmaceuticals to Participate in Upcoming Investor Conferences"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286156050.md"
description: "On May 12, 2026, in Deer Park, Illinois, Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a pharmaceutical company specializing in rare disease treatments, revealed that its executive team will attend three investor conferences."
datetime: "2026-05-12T20:32:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286156050.md)
  - [en](https://longbridge.com/en/news/286156050.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286156050.md)
---

# Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

On May 12, 2026, in Deer Park, Illinois, Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a pharmaceutical company specializing in rare disease treatments, revealed that its executive team will attend three investor conferences.

### Related Stocks

- [ETON.US](https://longbridge.com/en/quote/ETON.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)